Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.

Antimicrobial Agents and Chemotherapy
K S MacDonaldA R Ronald

Abstract

Chancroid is gaining importance as a sexually transmitted disease because of its association with transmission of human immunodeficiency virus type 1 (HIV-1). Effective, simply administered therapy for chancroid is necessary. Fleroxacin is effective against Haemophilus ducreyi in vitro. We performed an initial randomized clinical trial to assess the efficacy of fleroxacin for treatment of chancroid in Nairobi, Kenya. Fifty-three men with culture-positive chancroid were randomly assigned to receive either 200 mg (group 1) or 400 mg (group 2) of fleroxacin as a single oral dose. Groups 1 and 2 were similar with regard to severity of disease, bubo formation, and HIV-1 status. A satisfactory clinical response to therapy was noted in 23 of 26 patients (88%) in group 1 and 18 of 23 patients (78%) in group 2. Bacteriological failure occurred in 1 of 26 evaluable patients (4%) in group 1 and 4 of 23 evaluable patients (17%) in group 2. Two of 37 HIV-1-seronegative men (5%) and 3 of 11 HIV-1-infected men (27%) were bacteriological failures. Fleroxacin, 200 or 400 mg as a single oral dose, is efficacious therapy for microbiologically proven chancroid in patients who do not have concurrent HIV-1 infection. Among HIV-1-infected men, a sing...Continue Reading

References

Dec 11, 1987·JAMA : the Journal of the American Medical Association·G P SchmidE R Alexander
May 1, 1985·The Journal of Infectious Diseases·C A BlackmoreJ R Greenwood
Jun 1, 1988·Genitourinary Medicine·W NaamaraF A Plummer
Dec 1, 1987·Antimicrobial Agents and Chemotherapy·E WeidekammP W Lücker
Jul 1, 1986·Antimicrobial Agents and Chemotherapy·D A HaaseA R Ronald
Jul 14, 1983·The New England Journal of Medicine·F A PlummerA R Ronald
Feb 1, 1984·Antimicrobial Agents and Chemotherapy·B AndersonS R Johnson
Dec 1, 1984·The Journal of Antimicrobial Chemotherapy·P J McNicol, A R Ronald

❮ Previous
Next ❯

Citations

Oct 1, 1993·Antimicrobial Agents and Chemotherapy·A J FischmanH W Strauss
Jun 20, 2000·Sexually Transmitted Infections·D A Lewis
Feb 11, 2003·Sexually Transmitted Infections·D A Lewis
Feb 7, 1991·The New England Journal of Medicine·D C Hooper, J S Wolfson
Dec 15, 2004·Clinics in Dermatology·Jashin J WuStephen K Tyring
Sep 26, 2001·Protein Expression and Purification·R LawungL Bülow
May 28, 2005·Expert Review of Anti-infective Therapy·Naa Torshie Annan, David A Lewis
Aug 1, 2014·International Journal of STD & AIDS·Nigel O'Farrell, Neil Lazaro
Jan 1, 1996·International Journal of STD & AIDS·R C BallardF Radebe
Aug 17, 2012·The Cochrane Database of Systematic Reviews·Florence M MutuaCharles Shey Wiysonge
Sep 21, 2002·AIDS Patient Care and STDs·D A Lewis
Jan 5, 2008·International Journal of Dermatology·Tahir T Mohammed, Yetunde Mercy Olumide
Jul 28, 2005·The Journal of Antimicrobial Chemotherapy·Josée E Roy-LeonD William Cameron
Aug 23, 2000·Journal of the American Academy of Dermatology·A CzelustaS K Tyring
Jul 1, 1995·Clinical Microbiology Reviews·D L Trees, S A Morse
Jul 1, 1990·Antimicrobial Agents and Chemotherapy·Y DangorH J Koornhof

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.